WuXi AppTec (Shanghai) Co. Ltd.

TOLEDO, Ohio, March 3, 2025 /PRNewswire/ -- NAMSA, a leading US based MedTech testing, clinical and regulatory consulting firm, announced that it finalized its acquisition of WuXi AppTec's US medical device testing operations on February 28. The acquisition brings together two of the most trusted names in medical device biological safety testing, serving more than 4,000 manufacturers worldwide. Lisa Olson, NAMSA Senior Vice President of Global Laboratory Services notes: "Together, we now have unmatched scientific expertise in biocompatibility, microbiology, preclinical and extractables and leachables testing. With the addition of WuXi AppTec medical device testing facilities in the US, we now have more scientists, more lab capacity and more expertise with a wider variety of medical devices than any other company. This combined expertise will continue to enable our work with clients to develop testing and consulting strategies tailored to their specific device and regulatory pathways." NAMSA has been expanding its reach in recent years as it continues to diversify its offering beyond biological safety testing. Since 2021, the company has acquired no fewer than six companies focused on preclinical or clinical research, making NAMSA one of the leading MedTech focused CROs. Brian Smith, NAMSA's recently appointed CEO noted: "This acquisition is part of our larger strategy to broaden our service offering and solidify our position as the go-to resource for manufacturers bringing new life-saving technologies to market while upholding the same high standards of client focused service you have come to expect from NAMSA." About NAMSA Helping medical device Sponsors improve healthcare since 1967, NAMSA is a leading global MedTech testing, clinical and regulatory consulting firm. With a deep pool of testing, clinical and regulatory experts, and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development. From preclinical and clinical research to medical device testing and regulatory compliance, NAMSA is the industry's trusted partner for successful development and commercialization outcomes. Web: namsa.com Media Contact Chris Rupp Vice President Global Marketing & Commercial Operations Email: [email protected] SOURCE NAMSA WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

TOLEDO, Ohio, Feb. 24, 2025 /PRNewswire/ -- NAMSA, a world-leading MedTech testing, clinical and regulatory consulting firm, announced today that Brian P. Smith has taken on the role of NAMSA's next Chief Executive Officer. Most recently, Brian served as the Chairman and Chief Executive Officer of Ad-Tech Medical Instrument Corp., a leading US neuro-diagnostic company. Andre-Michel Ballester, NAMSA's outgoing CEO, will transition back into his role as a managing partner of ARCHIMED, the healthcare-focused global private equity firm that holds a majority stake in NAMSA. Ballester led the search for a new CEO and notes: "Brian is globally recognized as a respected healthcare executive, having served in various leadership roles over the past 15 years as a Board Member, Operating Partner, Chairman of the Board, and Chief Executive Officer with extensive experience in operational, commercial, and innovation strategies. Brian's international experience, having lived and worked in Hong Kong, Shanghai, and Singapore, will be invaluable as we continue to expand our global footprint." Smith adds: "I am thrilled to join an organization with the history, reputation, and contribution to improved patient outcomes that NAMSA has repeatedly demonstrated for decades. I look forward to making my own contribution to this ongoing success story." NAMSA recently announced that it had signed a definitive agreement to purchase the US medical device testing operations of WuXi AppTec. That transaction is expected to close in late February and Smith will play an instrumental role in ensuring a smooth transition of WuXi AppTec's business and customers to NAMSA. About NAMSA Helping medical device Sponsors improve healthcare since 1967, NAMSA is a leading global MedTech testing, clinical and regulatory consulting firm. With a deep pool of testing, clinical and regulatory experts, and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development. From preclinical and clinical research to medical device testing and regulatory compliance, NAMSA is the industry's trusted partner for successful development and commercialization outcomes. Web: namsa.com SOURCE North American Science Associates, LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

This winter has felt exceptionally long for the pharmaceutical industry. Since the summer of 2021, few anticipated that the downturn would extend beyond three and a half years, leading even the most patient investors to the brink of despair. As the CDMO sector begins to show signs of recovery, companies like WuXi AppTec have seen impressive rebounds—approximately 60% for WuXi PharmaTech and 110% for WuXi Biologics, with WuXi AppTec approaching historical highs. While a dramatic turnaround may not be in sight, even slight improvements could lead to significant elasticity in the market. In Q4 2024, public mutual funds' holdings in the pharmaceutical sector dropped to 8.58%, a 1.08 percentage point decline, hitting a historical low. This suggests that any minor influx of capital could yield substantial effects. The thawing of this prolonged winter is evident. On the payment side, a diversified payment system is expected to emerge, moving away from a single-payment structure. This change, alongside growing public concern over drug efficacy, may shift collective purchasing and insurance negotiations toward a balance of cost control and quality assurance. Additionally, the IPO market for unprofitable biotech firms might reopen, triggering a positive chain reaction. The spring for serious medical needs seems imminent, though consumer healthcare continues to face challenges. Traditional Chinese medicine is likened to the vaccines of three years ago, with the cold spell possibly just beginning. As of January 31, 278 pharmaceutical companies have released their 2024 earnings forecasts, with around 41% reporting positive net profit growth, while 59% anticipate declines. In the midst of widespread despair, the few companies achieving double-digit growth deserve recognition. The coming year marks a pivotal moment for both payment and financing avenues. The initial version of the Category B insurance directory is planned for release this year, signaling the formal establishment of an ecosystem for innovative drug payments. While changes may seem minor, they represent a significant beginning. Key developments include the long-awaited support for innovative drugs through commercial insurance, allowing these medications to enter the market more rapidly. The introduction of market-driven pricing for innovative drugs will also empower insurance companies, shifting the dynamic from a solely government-controlled system. The public's increasing focus on the efficacy of domestic drugs will not fade away with the upcoming Spring Festival. The prevailing sentiment is clear—price should not be the sole consideration. This perspective could lead to marginal improvements in future negotiations. The signs of thawing in financing for unprofitable biotech firms are also evident. On February 7, Dizhe Pharmaceuticals secured approval for an 18.5 billion yuan fundraising plan, marking the first unprofitable company to receive regulatory approval since the “Eight Regulations” initiative. As the capital market stabilizes, China’s innovative pharmaceuticals may see a rise in external business development prices as cash flow improves.